Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2025

Shelley Wood

February 28, 2025

News Daily News

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Michael O'Riordan

February 13, 2025

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

L.A. McKeown

August 30, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Todd Neale

October 20, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

Shelley Wood

October 01, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2020

Shelley Wood

January 31, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Carpal Tunnel Linked to Higher Rates of Amyloidosis and Heart Failure

L.A. McKeown

July 02, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Features

Year in Review: Physicians Pick the Biggest News of 2018

TCTMD News Team

December 29, 2018

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Shelley Wood

September 14, 2018

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

Advertisement

TCTMD’s Top 10 Most Popular Stories for February 2025

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

ATTRibute-CM Top-Line Results Favorable for Acoramidis

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

TCTMD’s Top 10 Most Popular Stories for September 2021

TCTMD’s Top 10 Most Popular Stories for January 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Carpal Tunnel Linked to Higher Rates of Amyloidosis and Heart Failure

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Year in Review: Physicians Pick the Biggest News of 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content